Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Unger

Showing results (1-10 of 219) with videos related to

Pageof 22
Sort By:
JAMA Network Open|April 20, 2021
Representativeness in Premarketing vs Postmarketing US Food and Drug Administration TrialsJoseph M Unger
Cancer|February 7, 2025
Financial toxicity: A ubiquitous condition in patients with cancerJoseph M Unger
JAMA Network Open|June 12, 2025
Inclusive Cancer Clinical Trial Participation-A Recipe for New Treatment AdvancesJoseph M Unger
JAMA Oncology|September 6, 2019
Reproducible Findings in Systematic Reviews and Meta-analyses in Oncology: Verify, Then TrustJoseph M Unger
JCO Oncology Practice|June 8, 2026
Psychosocial Predictors of Shared Decision Making Among US Cancer SurvivorsJoseph M Unger
Journal of the National Comprehensive Cancer Network : JNCCN|January 11, 2023
Lost in Translation: Participation in Cancer Clinical Trials for Patients With Limited English ProficiencyJoseph M Unger
JAMA Network Open|July 21, 2023
A Ground's-Eye View on Racial and Ethnic Disparities in Cancer Clinical Trial ParticipationJoseph M Unger
JAMA Network Open|June 23, 2026
Reporting of Rurality, Deprivation, and Socioeconomic Characteristics in Cancer Clinical Trials: A Systematic ReviewJoseph M Unger
JAMA Network Open|April 25, 2022
Cancer Care During COVID-19-A Shock to the SystemJoseph M Unger
Trials|April 9, 2021
The COVID-19 pandemic and new clinical trial activationsJoseph M Unger, Hong Xiao
Pageof 22

Showing results (1-10 of 219) with videos related to

Sort By:
Pageof 22
JAMA Network Open|April 20, 2021
Representativeness in Premarketing vs Postmarketing US Food and Drug Administration TrialsJoseph M Unger
Cancer|February 7, 2025
Financial toxicity: A ubiquitous condition in patients with cancerJoseph M Unger
JAMA Network Open|June 12, 2025
Inclusive Cancer Clinical Trial Participation-A Recipe for New Treatment AdvancesJoseph M Unger
JAMA Oncology|September 6, 2019
Reproducible Findings in Systematic Reviews and Meta-analyses in Oncology: Verify, Then TrustJoseph M Unger
JCO Oncology Practice|June 8, 2026
Psychosocial Predictors of Shared Decision Making Among US Cancer SurvivorsJoseph M Unger
Journal of the National Comprehensive Cancer Network : JNCCN|January 11, 2023
Lost in Translation: Participation in Cancer Clinical Trials for Patients With Limited English ProficiencyJoseph M Unger
JAMA Network Open|July 21, 2023
A Ground's-Eye View on Racial and Ethnic Disparities in Cancer Clinical Trial ParticipationJoseph M Unger
JAMA Network Open|June 23, 2026
Reporting of Rurality, Deprivation, and Socioeconomic Characteristics in Cancer Clinical Trials: A Systematic ReviewJoseph M Unger
JAMA Network Open|April 25, 2022
Cancer Care During COVID-19-A Shock to the SystemJoseph M Unger
Trials|April 9, 2021
The COVID-19 pandemic and new clinical trial activationsJoseph M Unger, Hong Xiao
Pageof 22